Connor Clark & Lunn Investment Management Ltd. Invests $18.18 Million in Thermo Fisher Scientific Inc. $TMO

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, HoldingsChannel.com reports. The firm acquired 36,269 shares of the medical research company’s stock, valued at approximately $18,184,000.

A number of other large investors have also made changes to their positions in the company. Brighton Jones LLC raised its position in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter worth $170,000. Raymond James Financial Inc. grew its holdings in Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after purchasing an additional 53,542 shares during the period. Finally, California State Teachers Retirement System increased its position in Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after buying an additional 2,262 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research report on Monday, July 6th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Royal Bank Of Canada upped their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Finally, Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $627.96 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market cap of $232.19 billion, a price-to-earnings ratio of 33.78, a PEG ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The stock’s 50 day simple moving average is $548.75 and its two-hundred day simple moving average is $510.05.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,493 shares of company stock worth $43,950,381 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.